About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
LPTX - LEAP THERAPEUTICS| Previous Close | $1.91 | Open | $1.94 |
| Volume | 547.3K | Market Cap | 33.74M |
| Yield | Last Dividend |
| Leap Therapeutics Reports Second Quarter... | 08/13/20 |
| CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immu... | |
| Leap Therapeutics Announces Closing of P... | 06/22/20 |
| CAMBRIDGE, Mass., June 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immu... | |
| Leap Therapeutics Announces Proposed Pub... | 06/17/20 |
| CAMBRIDGE, Mass., June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immu... | |
| Leap Therapeutics Reports First Quarter ... | 05/14/20 |
| CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immu... | |
| Leap Therapeutics to Present Updated Dat... | 04/23/20 |
| CAMBRIDGE, Mass., April 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and im... | |
| Leap Therapeutics to Present at Cowen 40... | 02/26/20 |
| CAMBRIDGE, Mass., Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and imm... | |
| The Daily Biotech Pulse: Heron Pain Drug... | 02/20/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) ... | |
| Leap Therapeutics to Present at 22nd Ann... | 02/04/20 |
| CAMBRIDGE, Mass., Feb. 4, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immu... | |
| NNVC, SLM, FCEL and TTPH among midday mo... | 01/23/20 |
| Gainers: Trans World Entertainment TWMC +260%. Co-Diagnostics CODX +89%. NanoViricides NNVC +55%. Kaleido BioSciences (NASDAQ:KLDO) +37%. Leap Therape... | |
| Leap's DKN-01 shows positive effect in e... | 01/23/20 |
| Updated results from a recently completed Phase 1/2 clinical trial, P102 (KEYNOTE-731), evaluating Leap Therapeutics' (NASDAQ:LPTX) DKN-01, combined w... | |
| Leap Therapeutics Presents Updated Data ... | 01/23/20 |
| CAMBRIDGE, Mass., Jan. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today presented updated clinical data from its recently complet... | |
| Leap Therapeutics Announces Closing of P... | 01/07/20 |
| CAMBRIDGE, Mass., Jan. 7, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immu... | |
| Leap Therapeutics Surges on License Agre... | 01/06/20 |
| Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs ... | |
| Leap Therapeutics (NASDAQ:LPTX) Stock Pr... | 11/16/19 |
| Shares of Leap Therapeutics Inc (NASDAQ:LPTX) dropped 46.1% during mid-day trading on Thursday . The company traded as low as $0.57 and last traded at... | |
| The Daily Biotech Pulse: Amarin Gets Una... | 11/15/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) ... | |
| Leap Therapeutics Reports Third Quarter ... | 11/14/19 |
| CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today reported financial results for the third quarter ended Sep... | |
| The Week Ahead In Biotech: Focus On Earn... | 08/03/19 |
| Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a ... | |
| The Week Ahead In Biotech: Pending Clini... | 07/27/19 |
| Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle ... | |
| Leap Therapeutics (LPTX) Investor Presen... | 04/10/19 |
| No summary available. | |
| Leap Therapeutics beats by $0.27 | 04/01/19 |
| No summary available. | |
| DSW and AQB among premarket losers | 03/19/19 |
| No summary available. | |
| RIOT, PXLW and ATOS among premarket gain... | 03/18/19 |
| No summary available. | |
| Leap up 52% premarket on positive DKN-01... | 03/18/19 |
| No summary available. | |
| CLNE, CARA, SYNA and NEOS among notable ... | 03/15/19 |
| No summary available. | |
| AVGO, BDSI and NVLN among premarket gain... | 03/15/19 |
| No summary available. | |
| COHU, NTRA, CARA and CLW among after hou... | 03/12/19 |
| No summary available. | |
| Seelos Therapeutics and Bio-Path Holding... | 03/12/19 |
| No summary available. | |
| Leap Therapeutics +3% as Valence Helix d... | 02/15/19 |
| No summary available. | |
| SWKS, SNAP, CPRI earnings dominate prema... | 02/06/19 |
| No summary available. | |
| Strong Buy rating | 06/29/20 |
| Piper Sandler initiates coverage with Overweight rating and announces Price Target of $6.00 | |
| Buy rating | 05/19/20 |
| and raises Price Target from $2.50 to $5.00 | |
| Date | 2020-08-13 (BMO) | Est. (EPS/Rev.) | ($0.18)/ 0 |
| Actual (EPS/Rev.) | $-0.12/ $375.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 84.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
